Zedoresertib clinical trials
Also written Debio 0123.
How each study uses zedoresertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zedoresertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Debiopharm International SA (4) · MedSIR (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test zedoresertib.
Studies
Open first, then newest update. How each study uses zedoresertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaRecruitingPhase 1/2Debiopharm International SANCT05765812Written as Zedoresertib
- A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid TumorsTerminatedPhase 1Debiopharm International SANCT05109975Written as Debio 0123
- Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based TherapyTerminatedPhase 1Debiopharm International SANCT05815160Written as Debio 0123
- Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast CancerActive, not recruitingPhase 1/2MedSIRNCT06612203Written as Debio 0123 and Sacituzumab govitecan
- Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid TumorsTerminatedPhase 1Debiopharm International SANCT03968653Written as Debio 0123
Given beside what is tested · 1 — zedoresertib is usual care or a partner of the new treatment
Codes
What other systems call zedoresertib · ClinicalTrials.gg INT017252
- UNII (FDA) M6Q5T59DJQZEDORESERTIBConfirmed FDA, Wikidata
- Wikidata Q140529372zedoresertibConfirmed FDA, Wikidata
- NCI Thesaurus C173426ZedoresertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M6Q5T59DJQ | ZEDORESERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529372 | zedoresertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C173426 | Zedoresertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.